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ABSTRACT: Here, we describe the discovery of a novel antimalarial agent using
phenotypic screening of Plasmodium falciparum asexual blood-stage parasites.
Screening a novel compound collection created using diversity-oriented synthesis
(DOS) led to the initial hit. Structure−activity relationships guided the synthesis of
compounds having improved potency and water solubility, yielding a subnanomolar
inhibitor of parasite asexual blood-stage growth. Optimized compound 27 has an
excellent off-target activity profile in erythrocyte lysis and HepG2 assays and is stable
in human plasma. This compound is available via the molecular libraries probe
production centers network (MLPCN) and is designated ML238.
KEYWORDS: diversity-oriented synthesis, malaria, macrocycle, high-throughput screening, phenotypic screen, infectious disease,
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M
alaria afflicts approximately 225 million people and leads
to ∼780 000 deaths per year.
1,2 The apicomplexan
Plasmodium parasite responsible for this condition is contracted
via Anopheles mosquito bites and lives a part of its life cycle
within this vector.
3 Endemic areas are limited to the tropics,
where continuous mosquito breeding is possible. Several species
of Plasmodium can infect mammalian hosts, and Plasmodium
falciparum is the most prevalent cause of fatal outcomes in
malaria patients.
4
Chemotherapy over a period of decades has likely contributed
to the high degree of genetic diversity within these parasites.
5
The emergence of resistance to antimalarial drugs has led to poor
treatment outcomes.
6 The current best practice is a combina-
tion therapy with the artemisinin family of antimalarial agents.
7
In addition to drug resistance, malaria is prevalent in under-
developed nations with poor infrastructures, high population
densities, and insufficient health care funding. These factors have
combined to present a challenging clinical environment.
8
Combination therapies have been used to mitigate the rate of
resistance in several diseases.
9 As such, new small molecules with
novel mechanism(s) of action have the greatest potential to
enable a successful path to the treatment of drug-resistant
malarial infections.
10,11
Diversity-oriented synthesis (DOS)
12−14 yields small mole-
cules having diverse stereochemistries and skeletons. Short,
modular synthetic pathways, for example, using the build/
couple/pair (B/C/P) strategy, facilitate downstream efforts
using medicinal chemistry. These novel compounds effectively
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15−21 Our recent
efforts
22 have focused on incorporating both structure−activity
relationships (SAR) and stereochemical structure−activity
relationships (SSAR) into the library design, thereby enabling
quick prioritization of hit clusters from primary screens.
Coupling this initial SAR with the ability to synthesize analogues
rapidly using modular synthetic pathways provides an efficient
process to pursue hits identified using high-throughput
screening (HTS). These principles were highlighted recently
by an aldol-based B/C/P strategy, resulting in compounds
having medium-sized and macrocyclic rings derived from a
common linear intermediate.
23,24 This report describes an HTS
that yielded novel compounds having antimalarial activity and
subsequent medicinal chemistry that yielded a promising and
novel subnanomolar inhibitor of the major etiologic agent of
severe malaria, P. falciparum.
We initiated the search for novel antimalarial agents via HTS
of an 8000-membered DOS 'informer' collection in a phenotypic
blood-stage malaria assay.
25 This representative set of com-
pounds was computationally selected for maximum diversity
representing all libraries in our collection while maintaining the
full complement of all possible stereoisomers of each compound.
HTS was conducted in triplicate at a 5 μM compound con-
centration using a growth inhibition assay (72 h, DAPI) with
Figure 1. Graphical depiction of the HTS triage.
Figure 2. Structure of lead compound 1, potency in two strains of
blood-stage malaria parasites, and the SSAR of the hit.
Table 1. SARs Derived from the Broad Compound
Collection
Figure 3. Preparation of derivatives in the solution phase.
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total of 560 compounds showed greater than 90% growth
inhibition, and titration at a four concentrations further narrowed
the list to 26 candidates (>50% inhibition at 280 nM). Of these,
20 compounds were from the 'ring-closing metathesis' (RCM)
library, and this scaffold was selected for further studies.
26
The most active hit (compound 1, Figure 2) was independently
synthesized and iteratively titrated in a 12-point assay to confirm a
potency (GI50) of 120 nM against Dd2 intraerythrocytic parasites
(GI50 values were obtained with Dd2 parasites unless otherwise
specified). This lead has a similar potency in the drug-sensitive
3d7 parasite strain and does not cause hemolysis of erythrocytes
at up to 40 μM concentration; unfortunately, it is largely insoluble
in aqueous solution (<0.5 μM in water). The stereochemical
SAR (SSAR) analysis of all 16 possible isomers of compound 1
demonstrates that interesting biological activity is predominantly
located in two stereoisomeric compounds that are epimeric
outside the macrocyclic ring (C2,F i g u r e2 ) .
In the first round of analogue testing, we searched the Broad
Institute chemical compound collection for analogues of hit 1
that had the same SRRS configuration (C2C5C6C12) and retained
one of the two (phenyl urea or 4-fluorophenyl sulfonamide) side
chain diversity elements. This exercise resulted in more than
50 available analogues. The results of selected titrations are
reported in Table 1. The first five structures show changes to the
amine side chain. Alternatively substituted and unsubstituted
sulfonamides 2 and 3 showed similar potency to the lead
(GI50 = 160 and 350 nM, respectively), while the corresponding
phenyl amide 4 (GI50 = 2600 nM) and benzyl amine 5 (GI50 =
1100 nM) demonstrated a loss in potency.
Alteration of the urea substituent from phenyl (1,L / D=1 2 0n M )
to isopropyl (6,G I 50 = 400 nM) or 2,4-dimethylisoxazolyl (7,
GI50 = 240 nM) afforded compounds with somewhat diminished
potency. Formal truncation of the urea to the dimethylaniline 8
(GI50 = >5000 nM) led to an inactive substrate, while the cor-
responding phenyl-sulfonamide 9 (GI50 = 2400 nM) also
provided a less biologically interesting substrate. The presence
of both reasonable SAR via the presence of close structural
analogues in the compound collection combined with promising
SSAR prompted additional investigation into this lead.
Independent preparation of interesting compounds and the
synthesis of additional derivatives closely followed the strategy
originally reported by Marcaurelle et al.
24 These syntheses were
performed in the solution phase. Protected intermediate 10 was
converted into the requisite derivatives via iterative capping and
deprotection steps (Figure 3). When the aniline group required
masking, a 9-fluorenylmethyloxycarbonyl (Fmoc) group was
used. Details of the synthetic steps used to prepare these
compounds can be found in the Supporting Information.
Our preliminary studies of the SAR of this novel lead
revolved around monitoring potency in the growth inhibition
assay while improving aqueous solubility by the addition of
polar functional groups and attempting to remove hydrophobic
bulk. We first directed our attention to the N,N′-diaryl urea
(Table 2). Formal truncation of the urea group provides the
corresponding aniline 11 (GI50 = 990 nM). Aniline 11, hetero-
cyclic aminobenzoxazole 12 (GI50 = 580 nM), and the
isopropyl urea 6 (GI50 = 400 nM) led to modest decreases in
potency. We followed on the observation that the isopropyl
Table 2. Initial SARs of the Aryl Substituent Table 3. Initial SARs at the Amine Substitutent
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solubility =2.2 μM) by independent preparation of the
heterocyclic and substituted 4-amino-3,5-dimethylisoxazolyl
urea 7. This afforded a soluble derivative (water solubility =
45 μM) with some loss of potency (GI50 = 240 nM).
We next optimized the amine side chain for potency and
solubility (Table 3). The regioisomeric 2-fluorophenylsulfon-
amide 13 has lower potency (GI50 = 1100 nM) when contrasted
with the parent, and the 4-trifluoromethyl derivative 14 showed
no improvement (GI50 = 880 nM). Hetereocycles such as
3-pyridylsulfonamide 15 were not tolerated (GI50 > 5000 nM),
and benzylic amine 16 also showed a lack of potency in the
primary phenotypic assay (GI50 = 4300 nM). Carbamate
derivatives such as tert-butyl (17), phenyl (18), and methox-
yethoxy (19) showed improvements in solubility but lost
biological activity (all GI50 > 1400 nM).
Exploration of alternate substituents of the amide group began
serendipitously with the submission of protected derivatives to
the growth inhibition assay (Table 4). The para-methoxybenzyl
(PMB) ether 20 showed subnanomolar potency (GI50 =0 . 1 8n M ) .
To confirm this result, other less lipophilic groups were
appended to the alcohol. Pivalate (21,G I 50 = 7.3 nM), benzoyl
(22,G I 50 = 15 nM), and methoxymethyl (23,G I 50 = 8.2 nM)
showed similar but somewhat diminished improvements in
potency. Unfortunately, none of these compounds were soluble
in water.
Displacement of the sterically hindered hydroxyl group within
1 with azide under Mitsunobu conditions afforded both a potent
derivative (24,G I 50 = 3.2 nM) and access to nitrogen-based
functional groups expected to improve water solubility
(Scheme1). Reduction provided soluble primary amine 25
(GI50 = 370 nM, water solubility = 268 μM). The corresponding
monomethylamine 26 showed no improvements over its parent
(GI50 = 79 nM, water solubility = 401 μM), while dimethylamino
derivative 27 demonstrated both subnanomolar potency (GI50 =
0.54 nM) and solubility in water (water solubility = 120 μM).
With this encouraging result in hand, we revisited the
alternate stereochemical series on the C2 carbon located outside
the macrocycle originally noted in the HTS screen (Table 5).
Independent synthesis and titration of our original HTS hits
showed that the two epimeric alcohols 1 and 28 had similar
potency (GI50 = 120 and 62 nM, respectively), while desmethyl
ethanol derivative 30 lost some activity (GI50 = 630 nM). As
previously noted, the addition of a PMB ether in the S-series
resulted in a 3−4 log improvement in potency (20,G I 50 = 0.18
nM, vida supra). When the same formal transformation was
performed on the epimeric (R) diastereomer and desmethyl
examples, no correspondingly large potency improvements
were observed (29,G I 50 = 36 nM; and 31,G I 50 = 55 nM).
Confident that we were operating on the optimal stereoisomer,
we nominated 27 as the Molecular Libraries Probe Production
Centers Network (MLPCN) probe (ML238) and submitted it
for further testing.
Compound 27 has subnanomolar activity in two P. falciparum
strains, and inhibition of parasite growth is not time dependent
(contrasting 48−96 h time points, Table 6). The compound is
more potent than chloroquine or artesunate and is similar in
potency to atovoquone (GI50 = 0.54 nM, all three known anti-
malarial agents were used as controls). This compound is
Table 4. Initial SARs at the Amide Substitutent Scheme 1. Synthesis of Probe 27 from Initial Lead 1
a
aReagents and conditions: (a) DPPA, DBU, THF, 87%. (b) PPh3,
H2O, THF, 76%. (c) CH2O, MgSO4,H 2O, DCM; then NaBH(OAc)3,
87%.
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(>40 μM) and HepG2 cells (>30 μM). In the presence of
human plasma, it is highly protein-bound (99%) and stable
(98% remaining at 5 h).
Studies of the mechanism of action of this new class of anti-
malarial agent are underway.
27 Secondary assays have confirmed
that representative compounds from this chemical series are
not inhibitors of dihydroorotate dehydrogenase (DHODH)
enzymes (human and parasite enzymes >30 μM).
28,29 This
compound (27) is available via the MLPCN and is designated
ML238.
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